共 473 条
[1]
Adjei AA(2001)Ras signaling pathway proteins as therapeutic targets Curr Pharm Des 7 1581-1594
[2]
Allegra CJ(2009)American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2091-2096
[3]
Jessup JM(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634
[4]
Somerfield MR(2001)Kirsten ras mutations in patients with colorectal cancer: the ′RASCAL II′ study Br J Cancer 85 692-696
[5]
Hamilton SR(1998)Kirsten ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL’ study J Natl Cancer Inst 90 675-684
[6]
Hammond EH(2004)Systematic review of genetic influences on the prognosis of colorectal cancer Br J Surg 91 1275-1291
[7]
Hayes DF(2009)A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer BMC Cancer 9 145-561
[8]
McAllister PK(2009)KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer Am J Ther 16 554-iv55
[9]
Morton RF(2005)Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell′Italia Meridionale (GOIM) prospective study Ann Oncol 16 iv50-1446
[10]
Schilsky RL(2002)Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype Ann Oncol 13 1438-202